Get the Stockscreener App
0.6836
0.57%
0.0039
After Hours:
.68
-0.0036
-0.53%
Tenaya Therapeutics Inc stock is traded at $0.6836, with a volume of 4.48M.
It is up +0.57% in the last 24 hours and down -7.27% over the past month.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
See More
Previous Close:
$0.6797
Open:
$0.71
24h Volume:
4.48M
Relative Volume:
0.96
Market Cap:
$148.00M
Revenue:
-
Net Income/Loss:
$-111.13M
P/E Ratio:
-0.5179
EPS:
-1.32
Net Cash Flow:
$-91.53M
1W Performance:
-8.85%
1M Performance:
-7.27%
6M Performance:
-9.70%
1Y Performance:
-23.83%
1-Day Range:
$0.6512
$0.7198
1-Week Range:
$0.65
$0.8601
52-Week Range:
$0.36
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.6836 | 147.16M | 0 | -111.13M | -91.53M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
Group Gp Lp Column III Sells 343,717 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock - MarketBeat
Breakouts Watch: Is Tenaya Therapeutics Inc a speculative investmentJuly 2025 Selloffs & Safe Entry Point Alerts - baoquankhu1.vn
Tenaya Therapeutics receives Nasdaq notice on minimum bid price and amends equity plan By Investing.com - Investing.com South Africa
Tenaya Therapeutics receives Nasdaq notice on minimum bid price and amends equity plan - Investing.com Nigeria
Guidance Update: Is Waton Financial Limited stock a good pick for beginnersGap Down & Consistent Return Investment Signals - baoquankhu1.vn
Tenaya Therapeutics Faces Nasdaq Deficiency, Amends Equity Plan - TipRanks
Tenaya Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq bid-price warning hits Tenaya Therapeutics (Nasdaq: TNYA) as equity inducement pool grows - Stock Titan
Update Report: Is Tenaya Therapeutics Inc a speculative investmentJuly 2025 Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Is Tenaya Therapeutics Inc. part of any ETF2025 Support & Resistance & Stepwise Swing Trade Plans - mfd.ru
Morgan Stanley reduces PT on Tenaya Therapeutics (TNYA), keeps constructive stance on US small- to mid-cap biotech - MSN
Assessing Tenaya Therapeutics (TNYA) Valuation After Its US$60 Million Capital Raise And Extended Cash Runway - Yahoo Finance
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Tenaya Therapeutics (TNYA) Valuation After 2026 Gene Therapy Updates And US$60 Million Capital Raise - Sahm
How Does Tenaya Therapeutics' (TNYA) Extended Cash Runway Reframe Its Cardiac Gene Therapy Ambitions? - Yahoo Finance
Tenaya Therapeutics appoints new interim principal accounting officer - MSN
Is Tenaya Therapeutics’ (TNYA) 2026 Gene Therapy Milestone Roadmap Reframing Its Long-Term Risk Profile? - simplywall.st
Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026 - Finviz
Tenaya Therapeutics announces orderly board leadership transition - MSN
Will Tenaya Therapeutics Inc. stock deliver shareholder valueGDP Growth & Real-Time Sentiment Analysis - bollywoodhelpline.com
9 Overlooked Growth Stocks to Buy - Insider Monkey
Morgan Stanley Reduces PT on Tenaya Therapeutics (TNYA), Keeps Constructive Stance on U.S. Small- to Mid-Cap Biotech - Insider Monkey
10 Stocks Under $1 That Will Explode - Insider Monkey
What catalysts could drive Tenaya Therapeutics Inc. stock higher2025 Trading Volume Trends & Fast Entry High Yield Tips - Улправда
Will Tenaya Therapeutics Inc. stock benefit from infrastructure spending2025 Macro Impact & Free Real-Time Market Sentiment Alerts - ulpravda.ru
Tenaya Therapeutics announces 2026 strategic priorities - MarketScreener
Tenaya Therapeutics Outlines 2026 Milestones Following Positive Interim Results from MyPEAK™-1 and RIDGE™-1 Trials - Quiver Quantitative
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones - GlobeNewswire
Is Tenaya Therapeutics Inc. stock supported by strong fundamentalsInflation Watch & Proven Capital Preservation Tips - ulpravda.ru
Gene therapy trials for inherited heart disease face big 2026 tests - Stock Titan
Why Tenaya Therapeutics Inc. stock could see breakout soonJuly 2025 Drop Watch & Consistent Income Trade Recommendations - Улправда
Published on: 2026-01-09 09:18:13 - Улправда
What insider trading reveals about Tenaya Therapeutics Inc. stockEntry Point & Consistent Return Investment Signals - Улправда
Published on: 2026-01-09 03:34:26 - Bộ Nội Vụ
Why Tenaya Therapeutics Inc. stock is trending among retail tradersJuly 2025 Rallies & Free Accurate Trade Setup Notifications - Улправда
How Tenaya Therapeutics Inc. stock reacts to Fed rate cutsEarnings Beat Highlights & Affordable Portfolio Building - ulpravda.ru
Tenaya Therapeutics Inc. (TNYA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Buy Signal: Is Tenaya Therapeutics Inc stock supported by strong fundamentalsPortfolio Update Report & Daily Volume Surge Signals - moha.gov.vn
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Gene therapy genie back in the bottle? - BioWorld MedTech
Tenaya Therapeutics price target lowered to $4 from $6 at Canaccord - MSN
Why Tenaya Therapeutics Inc. stock is rated strong buy2025 Price Momentum & Free Expert Verified Stock Movement Alerts - Bölüm Sonu Canavarı
Tenaya Therapeutics, Inc.(NasdaqGS: TNYA) added to NASDAQ Biotechnology Index - MarketScreener
Buyout Rumor: Why Tenaya Therapeutics Inc stock is recommended by analystsMarket Activity Report & Reliable Trade Execution Plans - moha.gov.vn
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):